Zobrazeno 1 - 10
of 79
pro vyhledávání: '"Campone, Mario"'
Autor:
Ginzac A; INSERM U1240 Imagerie Moléculaire et Stratégies Théranostiques (IMoST), Université Clermont Auvergne, Clermont-Ferrand, F- 63000, France. angeline.ginzac@clermont.unicancer.fr.; Centre d'Investigation Clinique UMR501, Clermont-Ferrand, F-63000, France. angeline.ginzac@clermont.unicancer.fr.; Département de Recherche Clinique, Délégation Recherche Clinique et Innovation, Centre Jean PERRIN, Clermont-Ferrand, F-63000, France. angeline.ginzac@clermont.unicancer.fr., Molnar I; INSERM U1240 Imagerie Moléculaire et Stratégies Théranostiques (IMoST), Université Clermont Auvergne, Clermont-Ferrand, F- 63000, France.; Centre d'Investigation Clinique UMR501, Clermont-Ferrand, F-63000, France.; Département de Recherche Clinique, Délégation Recherche Clinique et Innovation, Centre Jean PERRIN, Clermont-Ferrand, F-63000, France., Durando X; INSERM U1240 Imagerie Moléculaire et Stratégies Théranostiques (IMoST), Université Clermont Auvergne, Clermont-Ferrand, F- 63000, France.; Centre d'Investigation Clinique UMR501, Clermont-Ferrand, F-63000, France.; Département de Recherche Clinique, Délégation Recherche Clinique et Innovation, Centre Jean PERRIN, Clermont-Ferrand, F-63000, France.; Service d'oncologie médicale, Centre Jean PERRIN, Clermont-Ferrand, F-63000, France., Motte Rouge T; Service d'oncologie médicale, Centre Eugène MARQUIS, Rennes, France., Petit T; Service d'oncologie médicale, Institut de Cancérologie Strasbourg Europe, Strasbourg, France., D'hondt V; Service d'oncologie médicale, Institut du Cancer de Montpellier Val d'Aurelle, Montpellier, France., Campone M; Service d'oncologie médicale, Institut de Cancérologie de l'Ouest, René GAUDUCHEAU, Saint Herblain, France., Bonichon-Lamichhane N; Service d'oncologie médicale et radiothérapie, Clinique Tivoli, Bordeaux, France., Venat Bouvet L; Service d'oncologie médicale, CHU Dupuytren, Limoges, France., Levy C; Service d'oncologie médicale, Centre François BACLESSE, Caen, France., Augereau P; Service d'oncologie médicale, Institut de Cancérologie de l'Ouest, René GAUDUCHEAU, Saint Herblain, France., Pistilli B; Service d'oncologie médicale, Institut Gustave ROUSSY, Villejuif, France., Arsene O; Service d'oncologie médicale, Centre Hospitalier de Blois, Blois, France., Jouannaud C; Service d'oncologie médicale, Institut Jean GODINOT, Reims, France., Nguyen S; Service d'oncologie médicale, Centre Hospitalier de Pau, Pau, France., Cayre A; Service d'anatomopathologie, Centre Jean PERRIN, Clermont-Ferrand, France., Tixier L; Service d'anatomopathologie, Centre Jean PERRIN, Clermont-Ferrand, France., Mahier Ait Oukhatar C; Unicancer, Paris, France., Nabholtz JM; Centre d'oncologie, Université King Saud (Medical City), Riyadh, Arabi Saoudite., Penault-Llorca F; INSERM U1240 Imagerie Moléculaire et Stratégies Théranostiques (IMoST), Université Clermont Auvergne, Clermont-Ferrand, F- 63000, France.; Service d'anatomopathologie, Centre Jean PERRIN, Clermont-Ferrand, France., Mouret-Reynier MA; Service d'oncologie médicale, Centre Jean PERRIN, Clermont-Ferrand, F-63000, France.
Publikováno v:
Breast cancer research and treatment [Breast Cancer Res Treat] 2024 Jun; Vol. 205 (2), pp. 267-279. Date of Electronic Publication: 2024 Mar 07.
Autor:
Goetz MP; Mayo Clinic, Rochester, Minnesota., Hamilton EP; Sarah Cannon Research Institute, Tennessee Oncology PLCC, Nashville, Tennessee., Campone M; Institut de Cancerologie de l'Ouest, Angers Cedex, France., Hurvitz SA; University of California, Los Angeles, California., Cortes J; Oncology Department, International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Barcelona, Spain.; Department of Medicine, Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Madrid, Spain., Johnston S; The Royal Marsden NHS Foundation Trust, London, United Kingdom., Llombart-Cussac A; Hospital Arnau Vilanova, Valencia, Spain., Kaufman PA; University of Vermont Medical Center, Burlington, Vermont., Toi M; Kyoto University, Kyoto, Japan., Jerusalem G; CHU Liege and Liege University, Liege, Belgium., Graham H; Eli Lilly and Company, Indianapolis, Indiana., Wang H; Eli Lilly and Company, Indianapolis, Indiana., Jansen VM; Eli Lilly and Company, Indianapolis, Indiana., Litchfield LM; Eli Lilly and Company, Indianapolis, Indiana., Martin M; Instiuto de Investigacion Santaria Gregorio Maranon, Universidad Complutense, CIBERONC, Madrid, Spain.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 May 15; Vol. 30 (10), pp. 2233-2244.
Autor:
Campone M; Western Cancer Institute, Nantes, France. mario.campone@ico.unicancer.fr., De Laurentiis M; Istituto Nazionale Tumori IRCCS 'Fondazione Pascale', Naples, Italy., Zamagni C; IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy., Kudryavcev I; Kaluga Regional Clinical Oncology Center, Kaluga, Russian Federation., Agterof M; St. Antonius Hospital, Utrecht/Nieuwegein, The Netherlands., Brown-Glaberman U; University of New Mexico Cancer Center, Albuquerque, NM, USA., Palácová M; Masaryk Memorial Cancer Institute, Brno, Czech Republic., Chatterjee S; Tata Medical Center, Kolkata, India., Menon-Singh L; Novartis Pharmaceuticals, East Hanover, NJ, USA., Wu J; Novartis Pharmaceuticals, East Hanover, NJ, USA., Martín M; Gregorio Marañón General University Hospital, Madrid, Spain.
Publikováno v:
Breast cancer research and treatment [Breast Cancer Res Treat] 2022 May; Vol. 193 (1), pp. 95-103. Date of Electronic Publication: 2022 Feb 25.
Autor:
Hortobagyi GN; From the Department of Breast Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center (C.L.A.), and Baylor University Medical Center, Texas Oncology, US Oncology (J.O.), Dallas - all in Texas; the Institute of Oncology, Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel (S.M.S.); Sarah Cannon Research Institute, Nashville (H.A.B.); the Department of Medical Oncology, National Cancer Centre Singapore, Singapore (Y.-S.Y.); the Department of Medical Oncology, Netherlands Cancer Institute and Borstkanker Onderzoek Groep Study Center, Amsterdam (G.S.S.); Florida Cancer Specialists, Sarah Cannon Research Institute, Fort Myers (L.H.); the Department of Medical Oncology, Institut de Cancérologie de l'Ouest-René Gauducheau, Saint-Herblain (M.C.), and the Department of Medical Oncology, Institut Gustave Roussy, Medical School, Université Paris-Saclay, Villejuif (F.A.) - both in France; the Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (E.P.W.); the Department of Gynecology, University of Ulm, Ulm, Germany (W.J.); the Department of Surgery, Oncology, and Gastroenterology, University of Padua, and the Division of Medical Oncology 2, Istituto Oncologico Veneto, IRCCS, Padua, Italy (P.C.); the Edinburgh Cancer Research Centre, Institute of Genomics and Cancer, University of Edinburgh, Edinburgh (D.A.C.); Novartis Pharmaceuticals, East Hanover, NJ (J.P.Z., A.C.); and Novartis Pharma, Basel, Switzerland (T.T., F.L.G., P.S.)., Stemmer SM; From the Department of Breast Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center (C.L.A.), and Baylor University Medical Center, Texas Oncology, US Oncology (J.O.), Dallas - all in Texas; the Institute of Oncology, Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel (S.M.S.); Sarah Cannon Research Institute, Nashville (H.A.B.); the Department of Medical Oncology, National Cancer Centre Singapore, Singapore (Y.-S.Y.); the Department of Medical Oncology, Netherlands Cancer Institute and Borstkanker Onderzoek Groep Study Center, Amsterdam (G.S.S.); Florida Cancer Specialists, Sarah Cannon Research Institute, Fort Myers (L.H.); the Department of Medical Oncology, Institut de Cancérologie de l'Ouest-René Gauducheau, Saint-Herblain (M.C.), and the Department of Medical Oncology, Institut Gustave Roussy, Medical School, Université Paris-Saclay, Villejuif (F.A.) - both in France; the Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (E.P.W.); the Department of Gynecology, University of Ulm, Ulm, Germany (W.J.); the Department of Surgery, Oncology, and Gastroenterology, University of Padua, and the Division of Medical Oncology 2, Istituto Oncologico Veneto, IRCCS, Padua, Italy (P.C.); the Edinburgh Cancer Research Centre, Institute of Genomics and Cancer, University of Edinburgh, Edinburgh (D.A.C.); Novartis Pharmaceuticals, East Hanover, NJ (J.P.Z., A.C.); and Novartis Pharma, Basel, Switzerland (T.T., F.L.G., P.S.)., Burris HA; From the Department of Breast Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center (C.L.A.), and Baylor University Medical Center, Texas Oncology, US Oncology (J.O.), Dallas - all in Texas; the Institute of Oncology, Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel (S.M.S.); Sarah Cannon Research Institute, Nashville (H.A.B.); the Department of Medical Oncology, National Cancer Centre Singapore, Singapore (Y.-S.Y.); the Department of Medical Oncology, Netherlands Cancer Institute and Borstkanker Onderzoek Groep Study Center, Amsterdam (G.S.S.); Florida Cancer Specialists, Sarah Cannon Research Institute, Fort Myers (L.H.); the Department of Medical Oncology, Institut de Cancérologie de l'Ouest-René Gauducheau, Saint-Herblain (M.C.), and the Department of Medical Oncology, Institut Gustave Roussy, Medical School, Université Paris-Saclay, Villejuif (F.A.) - both in France; the Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (E.P.W.); the Department of Gynecology, University of Ulm, Ulm, Germany (W.J.); the Department of Surgery, Oncology, and Gastroenterology, University of Padua, and the Division of Medical Oncology 2, Istituto Oncologico Veneto, IRCCS, Padua, Italy (P.C.); the Edinburgh Cancer Research Centre, Institute of Genomics and Cancer, University of Edinburgh, Edinburgh (D.A.C.); Novartis Pharmaceuticals, East Hanover, NJ (J.P.Z., A.C.); and Novartis Pharma, Basel, Switzerland (T.T., F.L.G., P.S.)., Yap YS; From the Department of Breast Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center (C.L.A.), and Baylor University Medical Center, Texas Oncology, US Oncology (J.O.), Dallas - all in Texas; the Institute of Oncology, Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel (S.M.S.); Sarah Cannon Research Institute, Nashville (H.A.B.); the Department of Medical Oncology, National Cancer Centre Singapore, Singapore (Y.-S.Y.); the Department of Medical Oncology, Netherlands Cancer Institute and Borstkanker Onderzoek Groep Study Center, Amsterdam (G.S.S.); Florida Cancer Specialists, Sarah Cannon Research Institute, Fort Myers (L.H.); the Department of Medical Oncology, Institut de Cancérologie de l'Ouest-René Gauducheau, Saint-Herblain (M.C.), and the Department of Medical Oncology, Institut Gustave Roussy, Medical School, Université Paris-Saclay, Villejuif (F.A.) - both in France; the Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (E.P.W.); the Department of Gynecology, University of Ulm, Ulm, Germany (W.J.); the Department of Surgery, Oncology, and Gastroenterology, University of Padua, and the Division of Medical Oncology 2, Istituto Oncologico Veneto, IRCCS, Padua, Italy (P.C.); the Edinburgh Cancer Research Centre, Institute of Genomics and Cancer, University of Edinburgh, Edinburgh (D.A.C.); Novartis Pharmaceuticals, East Hanover, NJ (J.P.Z., A.C.); and Novartis Pharma, Basel, Switzerland (T.T., F.L.G., P.S.)., Sonke GS; From the Department of Breast Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center (C.L.A.), and Baylor University Medical Center, Texas Oncology, US Oncology (J.O.), Dallas - all in Texas; the Institute of Oncology, Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel (S.M.S.); Sarah Cannon Research Institute, Nashville (H.A.B.); the Department of Medical Oncology, National Cancer Centre Singapore, Singapore (Y.-S.Y.); the Department of Medical Oncology, Netherlands Cancer Institute and Borstkanker Onderzoek Groep Study Center, Amsterdam (G.S.S.); Florida Cancer Specialists, Sarah Cannon Research Institute, Fort Myers (L.H.); the Department of Medical Oncology, Institut de Cancérologie de l'Ouest-René Gauducheau, Saint-Herblain (M.C.), and the Department of Medical Oncology, Institut Gustave Roussy, Medical School, Université Paris-Saclay, Villejuif (F.A.) - both in France; the Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (E.P.W.); the Department of Gynecology, University of Ulm, Ulm, Germany (W.J.); the Department of Surgery, Oncology, and Gastroenterology, University of Padua, and the Division of Medical Oncology 2, Istituto Oncologico Veneto, IRCCS, Padua, Italy (P.C.); the Edinburgh Cancer Research Centre, Institute of Genomics and Cancer, University of Edinburgh, Edinburgh (D.A.C.); Novartis Pharmaceuticals, East Hanover, NJ (J.P.Z., A.C.); and Novartis Pharma, Basel, Switzerland (T.T., F.L.G., P.S.)., Hart L; From the Department of Breast Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center (C.L.A.), and Baylor University Medical Center, Texas Oncology, US Oncology (J.O.), Dallas - all in Texas; the Institute of Oncology, Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel (S.M.S.); Sarah Cannon Research Institute, Nashville (H.A.B.); the Department of Medical Oncology, National Cancer Centre Singapore, Singapore (Y.-S.Y.); the Department of Medical Oncology, Netherlands Cancer Institute and Borstkanker Onderzoek Groep Study Center, Amsterdam (G.S.S.); Florida Cancer Specialists, Sarah Cannon Research Institute, Fort Myers (L.H.); the Department of Medical Oncology, Institut de Cancérologie de l'Ouest-René Gauducheau, Saint-Herblain (M.C.), and the Department of Medical Oncology, Institut Gustave Roussy, Medical School, Université Paris-Saclay, Villejuif (F.A.) - both in France; the Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (E.P.W.); the Department of Gynecology, University of Ulm, Ulm, Germany (W.J.); the Department of Surgery, Oncology, and Gastroenterology, University of Padua, and the Division of Medical Oncology 2, Istituto Oncologico Veneto, IRCCS, Padua, Italy (P.C.); the Edinburgh Cancer Research Centre, Institute of Genomics and Cancer, University of Edinburgh, Edinburgh (D.A.C.); Novartis Pharmaceuticals, East Hanover, NJ (J.P.Z., A.C.); and Novartis Pharma, Basel, Switzerland (T.T., F.L.G., P.S.)., Campone M; From the Department of Breast Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center (C.L.A.), and Baylor University Medical Center, Texas Oncology, US Oncology (J.O.), Dallas - all in Texas; the Institute of Oncology, Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel (S.M.S.); Sarah Cannon Research Institute, Nashville (H.A.B.); the Department of Medical Oncology, National Cancer Centre Singapore, Singapore (Y.-S.Y.); the Department of Medical Oncology, Netherlands Cancer Institute and Borstkanker Onderzoek Groep Study Center, Amsterdam (G.S.S.); Florida Cancer Specialists, Sarah Cannon Research Institute, Fort Myers (L.H.); the Department of Medical Oncology, Institut de Cancérologie de l'Ouest-René Gauducheau, Saint-Herblain (M.C.), and the Department of Medical Oncology, Institut Gustave Roussy, Medical School, Université Paris-Saclay, Villejuif (F.A.) - both in France; the Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (E.P.W.); the Department of Gynecology, University of Ulm, Ulm, Germany (W.J.); the Department of Surgery, Oncology, and Gastroenterology, University of Padua, and the Division of Medical Oncology 2, Istituto Oncologico Veneto, IRCCS, Padua, Italy (P.C.); the Edinburgh Cancer Research Centre, Institute of Genomics and Cancer, University of Edinburgh, Edinburgh (D.A.C.); Novartis Pharmaceuticals, East Hanover, NJ (J.P.Z., A.C.); and Novartis Pharma, Basel, Switzerland (T.T., F.L.G., P.S.)., Petrakova K; From the Department of Breast Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center (C.L.A.), and Baylor University Medical Center, Texas Oncology, US Oncology (J.O.), Dallas - all in Texas; the Institute of Oncology, Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel (S.M.S.); Sarah Cannon Research Institute, Nashville (H.A.B.); the Department of Medical Oncology, National Cancer Centre Singapore, Singapore (Y.-S.Y.); the Department of Medical Oncology, Netherlands Cancer Institute and Borstkanker Onderzoek Groep Study Center, Amsterdam (G.S.S.); Florida Cancer Specialists, Sarah Cannon Research Institute, Fort Myers (L.H.); the Department of Medical Oncology, Institut de Cancérologie de l'Ouest-René Gauducheau, Saint-Herblain (M.C.), and the Department of Medical Oncology, Institut Gustave Roussy, Medical School, Université Paris-Saclay, Villejuif (F.A.) - both in France; the Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (E.P.W.); the Department of Gynecology, University of Ulm, Ulm, Germany (W.J.); the Department of Surgery, Oncology, and Gastroenterology, University of Padua, and the Division of Medical Oncology 2, Istituto Oncologico Veneto, IRCCS, Padua, Italy (P.C.); the Edinburgh Cancer Research Centre, Institute of Genomics and Cancer, University of Edinburgh, Edinburgh (D.A.C.); Novartis Pharmaceuticals, East Hanover, NJ (J.P.Z., A.C.); and Novartis Pharma, Basel, Switzerland (T.T., F.L.G., P.S.)., Winer EP; From the Department of Breast Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center (C.L.A.), and Baylor University Medical Center, Texas Oncology, US Oncology (J.O.), Dallas - all in Texas; the Institute of Oncology, Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel (S.M.S.); Sarah Cannon Research Institute, Nashville (H.A.B.); the Department of Medical Oncology, National Cancer Centre Singapore, Singapore (Y.-S.Y.); the Department of Medical Oncology, Netherlands Cancer Institute and Borstkanker Onderzoek Groep Study Center, Amsterdam (G.S.S.); Florida Cancer Specialists, Sarah Cannon Research Institute, Fort Myers (L.H.); the Department of Medical Oncology, Institut de Cancérologie de l'Ouest-René Gauducheau, Saint-Herblain (M.C.), and the Department of Medical Oncology, Institut Gustave Roussy, Medical School, Université Paris-Saclay, Villejuif (F.A.) - both in France; the Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (E.P.W.); the Department of Gynecology, University of Ulm, Ulm, Germany (W.J.); the Department of Surgery, Oncology, and Gastroenterology, University of Padua, and the Division of Medical Oncology 2, Istituto Oncologico Veneto, IRCCS, Padua, Italy (P.C.); the Edinburgh Cancer Research Centre, Institute of Genomics and Cancer, University of Edinburgh, Edinburgh (D.A.C.); Novartis Pharmaceuticals, East Hanover, NJ (J.P.Z., A.C.); and Novartis Pharma, Basel, Switzerland (T.T., F.L.G., P.S.)., Janni W; From the Department of Breast Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center (C.L.A.), and Baylor University Medical Center, Texas Oncology, US Oncology (J.O.), Dallas - all in Texas; the Institute of Oncology, Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel (S.M.S.); Sarah Cannon Research Institute, Nashville (H.A.B.); the Department of Medical Oncology, National Cancer Centre Singapore, Singapore (Y.-S.Y.); the Department of Medical Oncology, Netherlands Cancer Institute and Borstkanker Onderzoek Groep Study Center, Amsterdam (G.S.S.); Florida Cancer Specialists, Sarah Cannon Research Institute, Fort Myers (L.H.); the Department of Medical Oncology, Institut de Cancérologie de l'Ouest-René Gauducheau, Saint-Herblain (M.C.), and the Department of Medical Oncology, Institut Gustave Roussy, Medical School, Université Paris-Saclay, Villejuif (F.A.) - both in France; the Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (E.P.W.); the Department of Gynecology, University of Ulm, Ulm, Germany (W.J.); the Department of Surgery, Oncology, and Gastroenterology, University of Padua, and the Division of Medical Oncology 2, Istituto Oncologico Veneto, IRCCS, Padua, Italy (P.C.); the Edinburgh Cancer Research Centre, Institute of Genomics and Cancer, University of Edinburgh, Edinburgh (D.A.C.); Novartis Pharmaceuticals, East Hanover, NJ (J.P.Z., A.C.); and Novartis Pharma, Basel, Switzerland (T.T., F.L.G., P.S.)., Conte P; From the Department of Breast Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center (C.L.A.), and Baylor University Medical Center, Texas Oncology, US Oncology (J.O.), Dallas - all in Texas; the Institute of Oncology, Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel (S.M.S.); Sarah Cannon Research Institute, Nashville (H.A.B.); the Department of Medical Oncology, National Cancer Centre Singapore, Singapore (Y.-S.Y.); the Department of Medical Oncology, Netherlands Cancer Institute and Borstkanker Onderzoek Groep Study Center, Amsterdam (G.S.S.); Florida Cancer Specialists, Sarah Cannon Research Institute, Fort Myers (L.H.); the Department of Medical Oncology, Institut de Cancérologie de l'Ouest-René Gauducheau, Saint-Herblain (M.C.), and the Department of Medical Oncology, Institut Gustave Roussy, Medical School, Université Paris-Saclay, Villejuif (F.A.) - both in France; the Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (E.P.W.); the Department of Gynecology, University of Ulm, Ulm, Germany (W.J.); the Department of Surgery, Oncology, and Gastroenterology, University of Padua, and the Division of Medical Oncology 2, Istituto Oncologico Veneto, IRCCS, Padua, Italy (P.C.); the Edinburgh Cancer Research Centre, Institute of Genomics and Cancer, University of Edinburgh, Edinburgh (D.A.C.); Novartis Pharmaceuticals, East Hanover, NJ (J.P.Z., A.C.); and Novartis Pharma, Basel, Switzerland (T.T., F.L.G., P.S.)., Cameron DA; From the Department of Breast Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center (C.L.A.), and Baylor University Medical Center, Texas Oncology, US Oncology (J.O.), Dallas - all in Texas; the Institute of Oncology, Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel (S.M.S.); Sarah Cannon Research Institute, Nashville (H.A.B.); the Department of Medical Oncology, National Cancer Centre Singapore, Singapore (Y.-S.Y.); the Department of Medical Oncology, Netherlands Cancer Institute and Borstkanker Onderzoek Groep Study Center, Amsterdam (G.S.S.); Florida Cancer Specialists, Sarah Cannon Research Institute, Fort Myers (L.H.); the Department of Medical Oncology, Institut de Cancérologie de l'Ouest-René Gauducheau, Saint-Herblain (M.C.), and the Department of Medical Oncology, Institut Gustave Roussy, Medical School, Université Paris-Saclay, Villejuif (F.A.) - both in France; the Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (E.P.W.); the Department of Gynecology, University of Ulm, Ulm, Germany (W.J.); the Department of Surgery, Oncology, and Gastroenterology, University of Padua, and the Division of Medical Oncology 2, Istituto Oncologico Veneto, IRCCS, Padua, Italy (P.C.); the Edinburgh Cancer Research Centre, Institute of Genomics and Cancer, University of Edinburgh, Edinburgh (D.A.C.); Novartis Pharmaceuticals, East Hanover, NJ (J.P.Z., A.C.); and Novartis Pharma, Basel, Switzerland (T.T., F.L.G., P.S.)., André F; From the Department of Breast Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center (C.L.A.), and Baylor University Medical Center, Texas Oncology, US Oncology (J.O.), Dallas - all in Texas; the Institute of Oncology, Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel (S.M.S.); Sarah Cannon Research Institute, Nashville (H.A.B.); the Department of Medical Oncology, National Cancer Centre Singapore, Singapore (Y.-S.Y.); the Department of Medical Oncology, Netherlands Cancer Institute and Borstkanker Onderzoek Groep Study Center, Amsterdam (G.S.S.); Florida Cancer Specialists, Sarah Cannon Research Institute, Fort Myers (L.H.); the Department of Medical Oncology, Institut de Cancérologie de l'Ouest-René Gauducheau, Saint-Herblain (M.C.), and the Department of Medical Oncology, Institut Gustave Roussy, Medical School, Université Paris-Saclay, Villejuif (F.A.) - both in France; the Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (E.P.W.); the Department of Gynecology, University of Ulm, Ulm, Germany (W.J.); the Department of Surgery, Oncology, and Gastroenterology, University of Padua, and the Division of Medical Oncology 2, Istituto Oncologico Veneto, IRCCS, Padua, Italy (P.C.); the Edinburgh Cancer Research Centre, Institute of Genomics and Cancer, University of Edinburgh, Edinburgh (D.A.C.); Novartis Pharmaceuticals, East Hanover, NJ (J.P.Z., A.C.); and Novartis Pharma, Basel, Switzerland (T.T., F.L.G., P.S.)., Arteaga CL; From the Department of Breast Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center (C.L.A.), and Baylor University Medical Center, Texas Oncology, US Oncology (J.O.), Dallas - all in Texas; the Institute of Oncology, Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel (S.M.S.); Sarah Cannon Research Institute, Nashville (H.A.B.); the Department of Medical Oncology, National Cancer Centre Singapore, Singapore (Y.-S.Y.); the Department of Medical Oncology, Netherlands Cancer Institute and Borstkanker Onderzoek Groep Study Center, Amsterdam (G.S.S.); Florida Cancer Specialists, Sarah Cannon Research Institute, Fort Myers (L.H.); the Department of Medical Oncology, Institut de Cancérologie de l'Ouest-René Gauducheau, Saint-Herblain (M.C.), and the Department of Medical Oncology, Institut Gustave Roussy, Medical School, Université Paris-Saclay, Villejuif (F.A.) - both in France; the Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (E.P.W.); the Department of Gynecology, University of Ulm, Ulm, Germany (W.J.); the Department of Surgery, Oncology, and Gastroenterology, University of Padua, and the Division of Medical Oncology 2, Istituto Oncologico Veneto, IRCCS, Padua, Italy (P.C.); the Edinburgh Cancer Research Centre, Institute of Genomics and Cancer, University of Edinburgh, Edinburgh (D.A.C.); Novartis Pharmaceuticals, East Hanover, NJ (J.P.Z., A.C.); and Novartis Pharma, Basel, Switzerland (T.T., F.L.G., P.S.)., Zarate JP; From the Department of Breast Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center (C.L.A.), and Baylor University Medical Center, Texas Oncology, US Oncology (J.O.), Dallas - all in Texas; the Institute of Oncology, Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel (S.M.S.); Sarah Cannon Research Institute, Nashville (H.A.B.); the Department of Medical Oncology, National Cancer Centre Singapore, Singapore (Y.-S.Y.); the Department of Medical Oncology, Netherlands Cancer Institute and Borstkanker Onderzoek Groep Study Center, Amsterdam (G.S.S.); Florida Cancer Specialists, Sarah Cannon Research Institute, Fort Myers (L.H.); the Department of Medical Oncology, Institut de Cancérologie de l'Ouest-René Gauducheau, Saint-Herblain (M.C.), and the Department of Medical Oncology, Institut Gustave Roussy, Medical School, Université Paris-Saclay, Villejuif (F.A.) - both in France; the Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (E.P.W.); the Department of Gynecology, University of Ulm, Ulm, Germany (W.J.); the Department of Surgery, Oncology, and Gastroenterology, University of Padua, and the Division of Medical Oncology 2, Istituto Oncologico Veneto, IRCCS, Padua, Italy (P.C.); the Edinburgh Cancer Research Centre, Institute of Genomics and Cancer, University of Edinburgh, Edinburgh (D.A.C.); Novartis Pharmaceuticals, East Hanover, NJ (J.P.Z., A.C.); and Novartis Pharma, Basel, Switzerland (T.T., F.L.G., P.S.)., Chakravartty A; From the Department of Breast Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center (C.L.A.), and Baylor University Medical Center, Texas Oncology, US Oncology (J.O.), Dallas - all in Texas; the Institute of Oncology, Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel (S.M.S.); Sarah Cannon Research Institute, Nashville (H.A.B.); the Department of Medical Oncology, National Cancer Centre Singapore, Singapore (Y.-S.Y.); the Department of Medical Oncology, Netherlands Cancer Institute and Borstkanker Onderzoek Groep Study Center, Amsterdam (G.S.S.); Florida Cancer Specialists, Sarah Cannon Research Institute, Fort Myers (L.H.); the Department of Medical Oncology, Institut de Cancérologie de l'Ouest-René Gauducheau, Saint-Herblain (M.C.), and the Department of Medical Oncology, Institut Gustave Roussy, Medical School, Université Paris-Saclay, Villejuif (F.A.) - both in France; the Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (E.P.W.); the Department of Gynecology, University of Ulm, Ulm, Germany (W.J.); the Department of Surgery, Oncology, and Gastroenterology, University of Padua, and the Division of Medical Oncology 2, Istituto Oncologico Veneto, IRCCS, Padua, Italy (P.C.); the Edinburgh Cancer Research Centre, Institute of Genomics and Cancer, University of Edinburgh, Edinburgh (D.A.C.); Novartis Pharmaceuticals, East Hanover, NJ (J.P.Z., A.C.); and Novartis Pharma, Basel, Switzerland (T.T., F.L.G., P.S.)., Taran T; From the Department of Breast Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center (C.L.A.), and Baylor University Medical Center, Texas Oncology, US Oncology (J.O.), Dallas - all in Texas; the Institute of Oncology, Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel (S.M.S.); Sarah Cannon Research Institute, Nashville (H.A.B.); the Department of Medical Oncology, National Cancer Centre Singapore, Singapore (Y.-S.Y.); the Department of Medical Oncology, Netherlands Cancer Institute and Borstkanker Onderzoek Groep Study Center, Amsterdam (G.S.S.); Florida Cancer Specialists, Sarah Cannon Research Institute, Fort Myers (L.H.); the Department of Medical Oncology, Institut de Cancérologie de l'Ouest-René Gauducheau, Saint-Herblain (M.C.), and the Department of Medical Oncology, Institut Gustave Roussy, Medical School, Université Paris-Saclay, Villejuif (F.A.) - both in France; the Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (E.P.W.); the Department of Gynecology, University of Ulm, Ulm, Germany (W.J.); the Department of Surgery, Oncology, and Gastroenterology, University of Padua, and the Division of Medical Oncology 2, Istituto Oncologico Veneto, IRCCS, Padua, Italy (P.C.); the Edinburgh Cancer Research Centre, Institute of Genomics and Cancer, University of Edinburgh, Edinburgh (D.A.C.); Novartis Pharmaceuticals, East Hanover, NJ (J.P.Z., A.C.); and Novartis Pharma, Basel, Switzerland (T.T., F.L.G., P.S.)., Le Gac F; From the Department of Breast Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center (C.L.A.), and Baylor University Medical Center, Texas Oncology, US Oncology (J.O.), Dallas - all in Texas; the Institute of Oncology, Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel (S.M.S.); Sarah Cannon Research Institute, Nashville (H.A.B.); the Department of Medical Oncology, National Cancer Centre Singapore, Singapore (Y.-S.Y.); the Department of Medical Oncology, Netherlands Cancer Institute and Borstkanker Onderzoek Groep Study Center, Amsterdam (G.S.S.); Florida Cancer Specialists, Sarah Cannon Research Institute, Fort Myers (L.H.); the Department of Medical Oncology, Institut de Cancérologie de l'Ouest-René Gauducheau, Saint-Herblain (M.C.), and the Department of Medical Oncology, Institut Gustave Roussy, Medical School, Université Paris-Saclay, Villejuif (F.A.) - both in France; the Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (E.P.W.); the Department of Gynecology, University of Ulm, Ulm, Germany (W.J.); the Department of Surgery, Oncology, and Gastroenterology, University of Padua, and the Division of Medical Oncology 2, Istituto Oncologico Veneto, IRCCS, Padua, Italy (P.C.); the Edinburgh Cancer Research Centre, Institute of Genomics and Cancer, University of Edinburgh, Edinburgh (D.A.C.); Novartis Pharmaceuticals, East Hanover, NJ (J.P.Z., A.C.); and Novartis Pharma, Basel, Switzerland (T.T., F.L.G., P.S.)., Serra P; From the Department of Breast Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center (C.L.A.), and Baylor University Medical Center, Texas Oncology, US Oncology (J.O.), Dallas - all in Texas; the Institute of Oncology, Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel (S.M.S.); Sarah Cannon Research Institute, Nashville (H.A.B.); the Department of Medical Oncology, National Cancer Centre Singapore, Singapore (Y.-S.Y.); the Department of Medical Oncology, Netherlands Cancer Institute and Borstkanker Onderzoek Groep Study Center, Amsterdam (G.S.S.); Florida Cancer Specialists, Sarah Cannon Research Institute, Fort Myers (L.H.); the Department of Medical Oncology, Institut de Cancérologie de l'Ouest-René Gauducheau, Saint-Herblain (M.C.), and the Department of Medical Oncology, Institut Gustave Roussy, Medical School, Université Paris-Saclay, Villejuif (F.A.) - both in France; the Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (E.P.W.); the Department of Gynecology, University of Ulm, Ulm, Germany (W.J.); the Department of Surgery, Oncology, and Gastroenterology, University of Padua, and the Division of Medical Oncology 2, Istituto Oncologico Veneto, IRCCS, Padua, Italy (P.C.); the Edinburgh Cancer Research Centre, Institute of Genomics and Cancer, University of Edinburgh, Edinburgh (D.A.C.); Novartis Pharmaceuticals, East Hanover, NJ (J.P.Z., A.C.); and Novartis Pharma, Basel, Switzerland (T.T., F.L.G., P.S.)., O'Shaughnessy J; From the Department of Breast Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center (C.L.A.), and Baylor University Medical Center, Texas Oncology, US Oncology (J.O.), Dallas - all in Texas; the Institute of Oncology, Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel (S.M.S.); Sarah Cannon Research Institute, Nashville (H.A.B.); the Department of Medical Oncology, National Cancer Centre Singapore, Singapore (Y.-S.Y.); the Department of Medical Oncology, Netherlands Cancer Institute and Borstkanker Onderzoek Groep Study Center, Amsterdam (G.S.S.); Florida Cancer Specialists, Sarah Cannon Research Institute, Fort Myers (L.H.); the Department of Medical Oncology, Institut de Cancérologie de l'Ouest-René Gauducheau, Saint-Herblain (M.C.), and the Department of Medical Oncology, Institut Gustave Roussy, Medical School, Université Paris-Saclay, Villejuif (F.A.) - both in France; the Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (E.P.W.); the Department of Gynecology, University of Ulm, Ulm, Germany (W.J.); the Department of Surgery, Oncology, and Gastroenterology, University of Padua, and the Division of Medical Oncology 2, Istituto Oncologico Veneto, IRCCS, Padua, Italy (P.C.); the Edinburgh Cancer Research Centre, Institute of Genomics and Cancer, University of Edinburgh, Edinburgh (D.A.C.); Novartis Pharmaceuticals, East Hanover, NJ (J.P.Z., A.C.); and Novartis Pharma, Basel, Switzerland (T.T., F.L.G., P.S.).
Publikováno v:
The New England journal of medicine [N Engl J Med] 2022 Mar 10; Vol. 386 (10), pp. 942-950.
Autor:
Wen PY; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: patrick_wen@dfci.harvard.edu., Stein A; Department of Internal Medicine II (Oncology Center), University Medical Center Hamburg-Eppendorf, Hamburg, Germany., van den Bent M; Brain Tumor Center and Department of Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, Netherlands., De Greve J; University Hospital Vrije Universiteit Brussel, Brussels, Belgium., Wick A; Department of Neurology, University of Heidelberg, National Center for Tumor Diseases, Heidelberg, Germany., de Vos FYFL; Department of Medical Oncology, University Medical Center Utrecht, University Utrecht, Utrecht, Netherlands., von Bubnoff N; University Medical Center Freiburg, Freiburg, Germany; Department of Hematology and Oncology, Medical Center, University of Schleswig-Holstein, Lübeck, Germany., van Linde ME; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam, Netherlands., Lai A; Department of Neurology, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA., Prager GW; Department of Medicine I, AKH Wien, Medical University of Vienna, Vienna, Austria., Campone M; Institut de Cancérologie de l'Ouest, Saint-Herblain, France., Fasolo A; Department of Medical Oncology, Ospedale San Raffaele IRCCS, Milan, Italy., Lopez-Martin JA; 12 de Octubre University Hospital & Research Institute, Madrid, Spain., Kim TM; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea., Mason WP; University Health Network, University of Toronto, Toronto, ON, Canada., Hofheinz RD; University Hospital of Mannheim, Mannheim, Germany., Blay JY; Center Leon Berard & University Claude Bernard Lyon I, Lyon, France., Cho DC; New York Medical College, Valhalla, New York, NY, USA., Gazzah A; Gustave Roussy Cancer Institute, Villejuif, France., Pouessel D; Department of Medical Oncology & Clinical Research Unit, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France., Yachnin J; Karolinska University Hospital, Theme Cancer, Center for Clinical Cancer Studies, Solna, Sweden., Boran A; Global Drug Development, Oncology Development Unit, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Burgess P; Global Drug Development, Oncology Development Unit, Novartis Pharma AG, Basel, Switzerland., Ilankumaran P; Global Drug Development, Oncology Development Unit, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Gasal E; Global Drug Development, Oncology Development Unit, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Subbiah V; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Publikováno v:
The Lancet. Oncology [Lancet Oncol] 2022 Jan; Vol. 23 (1), pp. 53-64. Date of Electronic Publication: 2021 Nov 24.
Autor:
Ciruelos EM; Department of Medical Oncology, Breast Cancer Unit, Hospital Universitario 12 de Octubre, Madrid, Spain., Rugo HS; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA., Mayer IA; Division of Hematology/Oncology, Vanderbilt University Medical Center/Vanderbilt-Ingram Cancer Center, Nashville, TN., Levy C; Responsable de l'Institut Normand du Sein, Centre François Baclesse, Caen, France., Forget F; Oncologie CHA, Hôpital de Libramont, Vivalia, Libramont-Chevigny, Belgium., Delgado Mingorance JI; Oncology Department, University Hospital of Badajoz, Servicio Extremeño de Salud, Badajoz, Spain, and Hospital Infanta Cristina, Badajoz, Spain., Safra T; Medical Oncology and Radiotherapy, Tel Aviv Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel., Masuda N; Department of Surgery and Breast Oncology, National Hospital Organization Osaka National Hospital, Osaka, Japan., Park YH; Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea., Juric D; Departments of Hematology/Oncology and Medicine, Massachusetts General Hospital, Boston, MA., Conte P; Dipartimento Di Scienze Chirurgiche Oncologiche e Gastroenterologiche, Università di Padova and Oncologia Medica 2, Istituto Oncologico Veneto IRCCS, Padova, Italy., Campone M; Institut de Cancérologie de l'Ouest, Angers, France., Loibl S; German Breast Group, GBG Forschungs GmbH, Neu-Isenburg, Germany.; Center for Haematology and Oncology, Bethanien Hospital, Frankfurt, Germany., Iwata H; Department of Breast Oncology, Aichi Cancer Center, Nagoya, Japan., Zhou X; RTI Health Solutions, Research Triangle Park, NC., Park J; Novartis Pharmaceuticals Corporation, East Hanover, NJ., Ridolfi A; Global Medical Affairs Biostatistics, Novartis Pharma S.A.S., Rueil-Malmaison, France., Lorenzo I; Novartis Oncology, Madrid, Spain., André F; Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France.
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2021 Jun 20; Vol. 39 (18), pp. 2005-2015. Date of Electronic Publication: 2021 Mar 29.
Autor:
Cabel L; Curie, Saint Cloud, France. Electronic address: Luc.cabel@curie.fr., Carton M; Curie, Saint Cloud, France., Pistilli B; Gustave Roussy, Paris, France., Dalenc F; Claudius Regaud IUCT, Toulouse, France., Vanlemnens L; Centre Oscar Lambret, Lille, France., Levy C; Centre Francois Baclesse, Caen, France., Jacot W; ICM, Montpellier, France., Debled M; Institut Bergonie, Bordeaux, France., Loeb A; Centre Henri Becquere, Rouen, France., Hennequin A; Centre Georges-Francois Leclerc, Dijon, France., De la Motte Rouge T; Centre Eugene Marquis, Rennes, France., Laborde L; Institut Paoli-Calmettes, Marseille, France., Laurent C; Institut de Cancérologie Lorraine, Vandoeuvre-les-Nancy, France., Chamorey E; Centre Antoine Lacassagne, Nice, France., Parent D; Institut Jean Godinot, Reims, France., Petit T; Centre Paul Strauss, Strasbourg, France., Mouret-Reynier MA; Centre Jean Perrin, Clermont-Ferrand, France., Campone M; Institut de Cancérologie de L'Ouest, Angers et Nantes, France., Perrocheau G; Institut de Cancérologie de L'Ouest, Angers et Nantes, France., Labreveux C; Unicancer, Paris, France., Bachelot T; Centre Léon Bérard, Lyon, France., Robain M; Unicancer, Paris, France., Lerebours F; Curie, Saint Cloud, France.
Publikováno v:
Breast (Edinburgh, Scotland) [Breast] 2021 Apr; Vol. 56, pp. 18-25. Date of Electronic Publication: 2021 Jan 30.
Autor:
Cabel L; Department of Medical Oncology, Institut Curie, Paris, France.; Department of Medical Oncology, Institut Curie, Saint Cloud, France.; Circulating Tumor Biomarkers Laboratory, SIRIC2 Institut Curie, Paris, France.; UVSQ, Université Paris-Saclay, Saint Cloud, France., Berger F; Department of Biostatistics, Institut Curie, PSL Research University, Saint Cloud, France., Cottu P; Department of Medical Oncology, Institut Curie, Paris, France.; Department of Medical Oncology, Institut Curie, Saint Cloud, France., Loirat D; Department of Medical Oncology, Institut Curie, Paris, France.; Department of Medical Oncology, Institut Curie, Saint Cloud, France., Rampanou A; Circulating Tumor Biomarkers Laboratory, SIRIC2 Institut Curie, Paris, France., Brain E; Department of Medical Oncology, Institut Curie, Paris, France.; Department of Medical Oncology, Institut Curie, Saint Cloud, France., Cyrille S; Department of Biostatistics, Institut Curie, PSL Research University, Saint Cloud, France., Bourgeois H; Department of Medical Oncology, Centre Jean Bernard, Le Mans, France., Kiavue N; Department of Medical Oncology, Institut Curie, Paris, France.; Department of Medical Oncology, Institut Curie, Saint Cloud, France., Deluche E; Department of Medical Oncology, CHU de Limoges, Limoges, France., Ladoire S; Department of Medical Oncology, CLCC Georges François Leclerc, Dijon, France., Campone M; Department of Medical Oncology, Institut de cancérologie de l'Ouest, Saint-Herblain, France., Pierga JY; Department of Medical Oncology, Institut Curie, Paris, France.; Department of Medical Oncology, Institut Curie, Saint Cloud, France.; Circulating Tumor Biomarkers Laboratory, SIRIC2 Institut Curie, Paris, France.; Université de Paris, Paris, France., Bidard FC; Department of Medical Oncology, Institut Curie, Paris, France. fcbidard@curie.fr.; Department of Medical Oncology, Institut Curie, Saint Cloud, France. fcbidard@curie.fr.; Circulating Tumor Biomarkers Laboratory, SIRIC2 Institut Curie, Paris, France. fcbidard@curie.fr.; UVSQ, Université Paris-Saclay, Saint Cloud, France. fcbidard@curie.fr.
Publikováno v:
British journal of cancer [Br J Cancer] 2021 Mar; Vol. 124 (7), pp. 1207-1213. Date of Electronic Publication: 2021 Jan 21.
Autor:
Bachelot T; Department of Medical Oncology, Centre Léon Bérard, Lyon, France., Filleron T; Department of Biostatistics, Institut Claudius-Regaud, IUCT Oncopole, Toulouse, France., Bieche I; Department of Genetics, Institut Curie and Paris-Descartes University, Paris, France., Arnedos M; Department of Medical Oncology, Gustave Roussy, Université Paris Saclay, Villejuif, France., Campone M; Institut de Cancérologie de l'Ouest - René Gauducheau, Saint Herblain et Angers, France., Dalenc F; Department of Medical Oncology, Institut Claudius-Regaud, IUCT Oncopole and University of Paul Sabatier, Toulouse, France., Coussy F; Department of Medical Oncology, Institut Curie, Paris, France., Sablin MP; Department of Medical Oncology, Institut Curie, Paris, France., Debled M; Department of Medical Oncology, Institut Bergonié, Bordeaux, France., Lefeuvre-Plesse C; Department of Medical Oncology, Centre Eugène Marquis, Rennes, France., Goncalves A; Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France., Reynier MM; Department of Medical Oncology, Centre Jean Perrin, Clermont-Ferrand, France., Jacot W; Department of Medical Oncology, Institut de Cancérologie de Montpellier, Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194 and Montpellier Université, Montpellier, France., You B; Department of Medical Oncology, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL); Centre d'Investigation de Thérapeutiques en Oncologie et Hématologie de Lyon (CITOHL); Univ Lyon, Université Claude Bernard Lyon 1; EMR UCBL/HCL 3738; GINECO, Lyon, France.; Centre Hospitalier Lyon Sud, Pierre Bénite, France., Barthelemy P; Institut de Cancérologie Strasbourg, Strasbourg, France.; Hôpitaux Universitaire de Strasbourg, Strasbourg, France., Verret B; Department of Medical Oncology, Gustave Roussy, Université Paris Saclay, Villejuif, France., Isambert N; Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France., Tchiknavorian X; Centre Hospitalier Intercommunal Toulon La Seyne-sur-Mer, Hôpital Sainte Musse, Toulon, France., Levy C; Department of Medical Oncology, Centre François Baclesse, Caen, France., Thery JC; Department of Medical Oncology, Centre Henri Becquerel, University of Medicine of Rouen, Rouen, France., L'Haridon T; Centre Hospitalier Départemental de Vendée, La Roche Sur Yon, France., Ferrero JM; Department of Medical Oncology, Centre Antoine Lacassagne, University Côte d'Azur, Nice, France., Mege A; Institut Sainte Catherine, Avignon, France., Del Piano F; Hôpitaux du Leman, Thonon Les Bains, France., Rouleau E; Cancer Genetics Laboratory, Department of Pathology and Medical Biology, Gustave Roussy Cancer Campus, Villejuif, France., Tran-Dien A; INSERM UMR981 and Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.; Université Paris Saclay, Le Kremlin-Bicetre, France., Adam J; Department of Pathology, Gustave Roussy Cancer Campus, Villejuif, France.; INSERM U1186, Gustave Roussy Cancer Campus, Villejuif, France., Lusque A; Department of Biostatistics, Institut Claudius-Regaud, IUCT Oncopole, Toulouse, France., Jimenez M; Unicancer, Paris, France., Jacquet A; Unicancer, Paris, France., Garberis I; INSERM UMR981 and Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.; Université Paris Saclay, Le Kremlin-Bicetre, France., Andre F; Department of Medical Oncology, Gustave Roussy, Université Paris Saclay, Villejuif, France. fabrice.andre@gustaveroussy.fr.; INSERM UMR981 and Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France. fabrice.andre@gustaveroussy.fr.; Université Paris Saclay, Le Kremlin-Bicetre, France. fabrice.andre@gustaveroussy.fr.
Publikováno v:
Nature medicine [Nat Med] 2021 Feb; Vol. 27 (2), pp. 250-255. Date of Electronic Publication: 2021 Jan 18.
Autor:
Bardia A; Departments of Medicine and Hematology/Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. bardia.aditya@mgh.harvard.edu., Modi S; Breast Medicine Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York., Oliveira M; Department of Medical Oncology, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Cortes J; Department of Medical Oncology, Vall d'Hebron Institute of Oncology, Barcelona, Spain and IOB Institute of Oncology, Quirónsalud Group, Madrid and Barcelona, Spain., Campone M; Department of Oncology, Institute of Cancer Research, Pays de la Loire, France., Ma B; Department of Clinical Oncology, Phase 1 Clinical Trial Center, The Chinese University of Hong Kong, Hong Kong, China., Dirix L; Oncology Centre, Sint Augustinus Hospital, Antwerp, Belgium., Weise A; Department of Hematology & Oncology, Karmanos Cancer Institute, Detroit, Michigan., Hewes B; Medical Department, Repertoire Immune Medicines, Cambridge, Massachusetts., Diaz-Padilla I; Oncology Global Development, Merck Group, Eysins, Switzerland., Han Y; Biostatistics Department, Novartis Pharmaceuticals, East Hanover, New Jersey., Deshpande P; GDO Trial Management - Oncology, Novartis Pharmaceuticals, East Hanover, New Jersey., Samant TS; Pharmacokinetic Sciences, Novartis Pharmaceuticals, East Hanover, New Jersey., Lorenc KR; Global Development, Novartis Pharmaceuticals, East Hanover, New Jersey., He W; Biostatistics Department, Novartis Pharmaceuticals, East Hanover, New Jersey., Su F; Global Development, Novartis Pharmaceuticals, East Hanover, New Jersey., Chavez-MacGregor M; Department of Breast Medical Oncology, Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2020 Dec 15; Vol. 26 (24), pp. 6417-6428. Date of Electronic Publication: 2020 Sep 30.